MedTrace Logo

Randomized Controlled Clinical Outcomes of the Vanguard XP Bicruciate Knee System

NCT02175576 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2023-02-21

Study results available
· View outcomes & findings →

Summary

Randomized Controlled Study to determine if preservation of ligaments provides increased functional ability post-operatively in comparison to traditional TKA which sacrifices soft tissue.

Conditions

Interventions

DEVICE

Vanguard XP Bicruciate Knee System

The Vanguard XP is a bicruciate retaining total knee design and is constrained by natural soft tissue.

DEVICE

Vanguard CR Knee System

The Vanguard CR system requires the ACL to be sacrificed and is constrained by soft tissue and device design.

Sponsors & Collaborators

  • Zimmer Biomet

    lead INDUSTRY

Principal Investigators

  • Hillary Overholser · Zimmer Biomet

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02175576 on ClinicalTrials.gov